

02/08/02

(For new nonprovisional applications under 37 CFR 1.53(b))

## "EXPRESS MAIL CERTIFICATE"

EXPRESS MAIL MAILING LABEL NUMBER EV000523682US

DATE OF DEPOSIT: 08 February 2002

Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT)

Elsa Matos

SIGNATURE

Elsa Matos

J1017 U.S. PTO  
10/071338

02/08/02

APPLICATION ELEMENTS	
See MPEP chapter 600 concerning utility patent application contents.	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	7. <input checked="" type="checkbox"/> The Title of the Invention: Isolated 5R Clavams and Methods for Their Manufacture
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$740.00 Total Claims 7 - 20 = 0 x \$18 \$ 0.00 Independent Claims 3 - 3 = 0 x \$84 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$280 <b>TOTAL FILING FEE \$740.00</b> <input checked="" type="checkbox"/> Cancel in this application original claims 1 to 37 of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge \$740.00 to the above indicated Deposit Account.	8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission from Appln. Serial No. 09/018,806 filed 04 February 1998. a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. 09/018,806, filed February 4, 1998 as the computer-readable form for the instant application. (37 CFR 1.821(e))
3. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] 33 4. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] 1 5. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] 16	9. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
6. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] 3 a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input type="checkbox"/> Unsigned Declaration [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
7. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: SmithKline Beecham p.l.c. and The Governors of the University of Alberta (for continuation/divisional with Box 17a completed)
17. <input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information	12. <input checked="" type="checkbox"/> Preliminary Amendment [2]
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09/018,806 filed February 4, 1998.	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed	14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. 09/018,806 filed 04 February 1998, which claims priority of Great Britain Application GB 9702218.0 filed 04 February 1997.	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/018,806 filed February 4, 1998. A PTO-1449 listing the references is enclosed.
Correspondence Address: GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone (610) 270-5024 Fax (610) 270-5090	16. <input type="checkbox"/> Other: Signature Name: Respectfully Submitted, Zoltan Kerekes Registration No. 38,938



20462

PATENT TRADEMARK OFFICE

**CERTIFICATE OF MAILING**  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE  
UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS  
MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER OF PATENTS AND  
TRADEMARKS, WASHINGTON, D.C. 20231,  
ON 21 AUGUST 1998

\_\_\_\_\_  
AGENT/ATTORNEY FOR APPLICANT

\_\_\_\_\_  
DATE

J1017 U.S. PTO  
10/071338  
02/08/02

Attorney Docket No.: P31731

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barton et al. August 21, 1998  
Serial No.: 09/018,806 Group Art Unit No.: 1652  
Filed: February 4, 1998 Examiner: B. Mayhew  
For: "Novel Compounds"

**AMENDMENT, STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Please insert the sequence listing sheets filed herewith after page 30 of the  
specification and renumber the specification accordingly.

- ( X ) I hereby state that the contents of the paper and computer readable copies of the  
Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and (e),  
respectively, are the same.
- ( X ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)**  
does not include new matter.
- ( ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)**  
does not include new matter or go beyond the disclosure in the international  
application as filed.
- ( ) I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**,  
included in the substitute sheet(s) of the Sequence Listing are supported in the  
application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheet(s) of  
the Sequence Listing does (do) not include new matter.

Serial No.: 09/018,806  
Group Art Unit No.: 1652

- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,



Zoltan Kerekes  
Attorney for Applicants  
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5024  
Facsimile (610) 270-5090  
N:\ZK\APPS\IP3173\VTSEQUEN.DOC